Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sinbaglustat (OGT2378) (OGT2378) is a dual inhibitor of glucose ceramide synthetase (GCS) and non-lysosomal glucose ceramidase (GBA2).Sinbaglustat is an orally administered N-alkyl iminosugar that crosses the blood-brain barrier.Sinbaglustat is used for the treatment of lysosomal storage disorders and for the study of central neurodegenerative disorders associated with lysosomal dysfunction. Sinbaglustat is used for the treatment of lysosomal storage disorders and for the study of lysosomal dysfunction-related central neurodegenerative diseases.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 157.00 | |
5 mg | In stock | $ 397.00 | |
10 mg | In stock | $ 595.00 | |
25 mg | In stock | $ 949.00 | |
50 mg | In stock | $ 1,290.00 | |
100 mg | In stock | $ 1,730.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 360.00 |
Description | Sinbaglustat (OGT2378) (OGT2378) is a dual inhibitor of glucose ceramide synthetase (GCS) and non-lysosomal glucose ceramidase (GBA2).Sinbaglustat is an orally administered N-alkyl iminosugar that crosses the blood-brain barrier.Sinbaglustat is used for the treatment of lysosomal storage disorders and for the study of central neurodegenerative disorders associated with lysosomal dysfunction. Sinbaglustat is used for the treatment of lysosomal storage disorders and for the study of lysosomal dysfunction-related central neurodegenerative diseases. |
In vitro |
Sinbaglustat (OGT2378) (20 μM) leads to a remarkable reduction in the synthesis of glucosylceramide by 93% and ganglioside by >95% when compared to untreated MEB4 cells. This reduction occurs without inducing any cytotoxicity or antiproliferative effects.[1] Sinbaglustat is 50-fold more potent in inhibiting GBA2 than GCS.[2] |
In vivo | Sinbaglustat (OGT2378) (2500 mg/kg/day; p.o.; in the powdered chow; corresponding to 35-40 mg/mouse/day of Sinbaglustat; Female syngeneic C57BL/6 mice and bearing MEB4 melanoma tumor, 6-8 weeks old bearing MEB4 melanoma tumor) is highly effective in impeding melanoma tumor growth in vivo. The effectiveness of p.o. Sinbaglustat in this murine model suggests that inhibition of glycosphingolipid synthesis is a promising approach to inhibit tumor progression.[1] |
Synonyms | ACT-519276, Sinbaglustat, OGT2378 |
Molecular Weight | 233.3 |
Formula | C11H23NO4 |
CAS No. | 441061-33-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 46.66 mg/mL (200 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Sinbaglustat 441061-33-2 Metabolism Transferase OGT 2378 ACT-519276 ACT519276 OGT-2378 OGT2378 ACT 519276 inhibitor inhibit